Decoding the antineoplastic efficacy of Aplysin targeting Bcl-2: A de novo perspective

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• The B-cell lymphoma-2 (Bcl-2) protein family regulates apoptosis and is crucial in human cancer development.
• Targeting Bcl-2 proteins offers a promising strategy for novel anticancer drug discovery.
• Inhibiting Bcl-2 or Bcl-XL can induce apoptosis in tumor cells and enhance sensitivity to therapies.

Purpose of the Study:

• To identify novel small molecules that inhibit Bcl-2 proteins.
• To explore the potential of Aplysin analogs as anticancer agents.
• To utilize computational methods for drug discovery.

Main Methods:

• Sequential virtual screening incorporating drug-like, ADMET, docking, and pharmacophore filters.
• Molecular dynamics simulations were employed to assess binding and stability.
• Comparative analysis with the standard drug Obatoclax.

Main Results:

• Novel Aplysin analogs were identified as potential Bcl-2 inhibitors.
• Compound analog 11 demonstrated significant inhibitory potential in docking, pharmacophore, and simulation models.
• The identified analogs show promise comparable to Obatoclax.

Conclusions:

• Aplysin analogs represent a promising class of compounds for developing novel Bcl-2 inhibitors.
• Computational modeling provides a vital foundation for designing effective Bcl-2 targeted cancer therapies.
• Further research into these analogs could lead to new anticancer drugs.